Financial Survey: WORK Medical Technology Group (NASDAQ:WOK) & TransMedics Group (NASDAQ:TMDX)

TransMedics Group (NASDAQ:TMDX) and WORK Medical Technology Group (NASDAQ:WOK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation.

Earnings and Valuation

This table compares TransMedics Group and WORK Medical Technology Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49 million	5.73	$190.29 million	$4.90	20.64
WORK Medical Technology Group	$9.81 million	0.00	-$1.07 million	N/A	N/A

TransMedics Group has higher revenue and earnings than WORK Medical Technology Group.

Volatility & Risk

TransMedics Group has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, WORK Medical Technology Group has a beta of 2.66, suggesting that its stock price is 166% more volatile than the S&P 500.

Insider & Institutional Ownership

99.7% of TransMedics Group shares are held by institutional investors. 7.0% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares TransMedics Group and WORK Medical Technology Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TransMedics Group	31.43%	30.17%	11.39%
WORK Medical Technology Group	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for TransMedics Group and WORK Medical Technology Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0	5	7	0	2.58
WORK Medical Technology Group	1	0	0	0	1.00

TransMedics Group presently has a consensus target price of $152.33, indicating a potential upside of 50.62%. Given TransMedics Group’s stronger consensus rating and higher possible upside, analysts plainly believe TransMedics Group is more favorable than WORK Medical Technology Group.

Summary

TransMedics Group beats WORK Medical Technology Group on 11 of the 12 factors compared between the two stocks.

About TransMedics Group

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

About WORK Medical Technology Group

WORK Medical Technology Group Ltd. engages in developing health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.